Group items tagged

This study looked at declining testosterone in Japanese men. The significant decrease was found in those men between 20 and through 40s.  Beyond which statistical decline was not found.  Also of note, lower salivary testosterone was associated with higher BMI

Study finds suggestion of cognitive protection by enduring estrogen exposure.  Interesting, that estrogen seems to protect against cognitive decline in women, yet increases cognitive decline in men.

This article discusses the failure of androgen deprivation therapy and prostate cancer.  This failure is quite common.  The authors point to alpha-DHT as the primary mechanism through AR stimulation.  However, we know that DHT metabolites also stimulate estrogen receptors.

This study found that lower TT and E1 associated with more "poor health" as defined by questionnaire.  The conclusion might lead one to think that Estrogen therapy is need in men.  Eightly percent of estrogen production in men occurs from Testosterone.  If Testosterone declines, then estrogen production will likewise decline.  A simple fact that the authors did not comment on.  Also, E1 binds with high affinity to ER alpha, which is pro-inflammatory and pro-proliferative: neither of which is a positive health benefit.   This appears to point more to a broad HPA suppression as an association to the "poor health".

estrogen therapy in surgical menopause preserves memory.  Rapid decline in estrogen levels post surgical menopause is associated with cognitive/memory decline.  Versus placebo, estrogen therapy preserved memory function.

This was the WHI review of data as it pertains to dementia and cognitive decline in women.  The take home here is that the data provides little evidence for premarin with or without medroxyprogesterone acetate in > 65 for prevention of dementia.  However, this is in women > 65 and studies show that younger women do indeed receive benefit, especially in those with early ovary removal.  Another point here, MPA (medroxyprogesterone acetate) increases cognitive decline.  Just don't take MPA, it is a bad drug all the way around!

The author's conclusion of this study found no difference in decline in blood pressure with/without estrogen therapy.  However, if you look at the results, the nonusers of estrogen did not have a decline in systolic blood pressure as in the users of estrogen.  So, I don't know where that conclusion comes from.  This study looked at lifestyle changes.  This study also found no benefit of metformin in blood pressure

This article summarizes it all.  With age, Testosterone declines and estrogen production, through elevated aromatase activity, increases.  This results in a decline in the Testosterone:estradiol ratio.  This has been clearly implicated in both benign and disease states of the prostate.  The evidence points to aromatase activity and estrogen in the prostate to poor prostate health.  Additionally, this article points out the impact of ER alpha and ER beta on the translation of the message of Estrogen.

Article links Fructose, to obesity and cognitive decline.

Study describes the link between fructose, obesity and cognitive decline.

15% decline in Testosterone found in American men from 1987 to 2004

Declining Testosterone, calculated free Testosterone, Estradiol, and Estrone levels appear to be associated with muscle mass/strength decline in elderly men.  This points to a global decrease in HPA function rather than an individual, specific hormone deficiency.

Study finds age and BMI associated decline in serum Testosterone levels in Finnish men.  This decline was worsened in more recently born age groups evaluated.

MMAS study finds an age associated decline in Total Testosterone and free Testosterone levels. This study focus on the % decline based on other variables i.e. age, BMI...IN contrast, a 3.5% rise in DHT levels were observed. There is debate about the correlation of serum DHT and intra-tissue DHT. In fact, studies suggest there is little correlation.

Obesity is associated with low Testosterone and ED in men.

More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision - declining recommendation of romosozumab, the first new osteoporosis medication for over a decade. In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease. The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research. It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures. Craig Jones, chief executive of the Royal Osteoporosis Society said: "We're calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.

short term use of anti-cholinergics linked to cognitive decline.

DHEAS declines with aging.

Just an association, but low vitamin  D levels found to be associated with decreased cognitive function in older women.  Found in women with levels < 20.

NAD found to slow mitochondrial decline associated with aging.  SIRT1 is involved; interesting of note is the inverse association with HIF-1alpha